Single-agent Pembrolizumab as a second-line treatment for metastatic NSCLC patients with PD-L1 TPS ≥ 1% provided a sustained and clinically meaningful improvement in PFS and OS, with more than doubled 5-year OS rate compared to docetaxel (20). This evidence concerns the gene CD274 and non-small cell lung carcinoma.